Clinical trials
HER 2 Negative Breast Cancer clinical trials
Below are recruiting her 2 negative breast cancer clinical trials, each written for real people, not researchers. We’re tracking 934 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT07581834RecruitingPhase 2
Dalpiciclib plus hormone therapy for early hormone-positive breast cancer
This study tests whether adding a new drug called dalpiciclib to standard hormone therapy improves outcomes for women with early-stage breast cancer that is hormone-receptor positive. The goal is to see if this combination is more effective and safe than hormone therapy alone.
Fuzhou, FujianAges 18 years+ - NCT05983107RecruitingPhase 2
Chidamide/Everolimus for advanced breast cancer
This trial tests a combination of two drugs, chidamide and everolimus, for people with advanced HR+/HER2- breast cancer. It aims to see if the combination works for tumors with or without a PIK3CA gene mutation. You may be able to join if you've had previous treatment with CDK4/6 inhibitors and up to two prior chemotherapies.
Beijing, Beijing MunicipalityAges 18–75 - NCT05625659Recruiting
Breast cancer screening for dense breasts using new X-ray scans
This trial compares two imaging tests—CESM (a contrast-enhanced mammogram) and DBT (3D mammography)—to see which works best for women with dense breast tissue. It may help improve how early breast changes are found in dense breasts.
Birmingham, AlabamaAges 45–74 - NCT04315233RecruitingPhase 1
Testing two drugs for hard-to-treat triple-negative breast and ovarian cancer
This Phase 1 trial tests ribociclib plus belinostat in people with metastatic triple-negative breast cancer or recurrent ovarian cancer. It also looks at your tumor’s genetics (from a fresh biopsy) to see who might respond better.
Salt Lake City, UtahAges 18 years+ - NCT07115043RecruitingPhase 1/Phase 2
Study of AZD6750 for advanced solid tumors
This trial tests a new drug called AZD6750 for people with advanced solid tumors that have not responded to standard treatments. It aims to see if the drug is safe and effective.
Grand Rapids, MichiganAges 18 years+ - NCT07354919RecruitingPhase 2
Testing axelopran for advanced cancer patients on opioids
This trial tests if axelopran can help people with advanced prostate, breast, pancreatic, or lung cancer who are taking opioid pain medicines. It aims to see if the drug is safe and helps with bowel function.
Saint Louis Park, MinnesotaAges 18 years+ - NCT06891833RecruitingPhase 2/Phase 3
New drug combo for HER2-positive breast cancer before surgery
This trial tests a new targeted drug (BL-M07D1) with or without another drug called pertuzumab, compared to a standard chemotherapy plus two targeted drugs, before surgery for HER2-positive breast cancer. The goal is to see if the new combination works better at shrinking tumors before surgery.
Bengbu, AnhuiAges 18–75 - NCT05306041RecruitingPhase 2
Pre-surgery hormone therapy with or without PI3K inhibitor
This trial tests whether giving hormone-blocking treatment before surgery works better when combined with an added targeted drug for certain breast cancers. It may help shrink the tumor and improve outcomes for people whose tumors have specific hormone and genetic features.
Essen, North Rhine-WestphaliaAges 18 years+ - NCT06957886RecruitingPhase 3
Study of BL-M07D1 vs chemo for HER2-low breast cancer
This trial tests a new drug, BL-M07D1, against standard chemotherapy for people with HER2-low breast cancer that has spread or come back. It aims to find which treatment works better.
Guangzhou, GuangdongAges 18–75 - NCT04481932RecruitingPhase 2
Trastuzumab with chemo for HER2-positive breast cancer
This Phase 2 study tests whether adding trastuzumab (a targeted antibody) given with chemo and extra drugs can better treat certain HER2-positive, locally advanced or inflammatory breast cancers. It may help by improving cancer control in people who have not had prior anti-cancer treatment for their breast cancer.
Beijing, Beijing MunicipalityAges 18–70 - NCT07616453RecruitingPhase 2
New Drug Plus Hormone Therapy for Hormone-Responsive Breast Cancer
This trial tests whether a new drug called culmerciclib, combined with hormone therapy, works better than hormone therapy alone for early-stage breast cancer that grows quickly and responds to estrogen. The goal is to shrink tumors before surgery and improve outcomes.
Hangzhou, ZhejiangAges 18–75 - NCT05955170RecruitingPhase 2
Tucatinib plus oral chemo and trastuzumab for metastatic HER2+ breast cancer
This Phase 2 trial studies tucatinib combined with oral etoposide and trastuzumab in people with metastatic HER2-positive breast cancer, aiming to slow cancer growth. You may be eligible if you previously had progression on a similar HER2-targeted treatment or cannot take capecitabine for medical reasons.
Clermont-Ferrand, Clermont FerrandAges 18 years+ - NCT07377643RecruitingPhase 3
New drug combo for advanced HER2-positive breast cancer
This trial tests a new drug called IBI354 (an antibody-drug conjugate) given with or without pertuzumab, compared to the standard combination of taxane, trastuzumab, and pertuzumab, for people with HER2-positive breast cancer that has spread and who have not had prior treatment for advanced disease.
Beijing, Beijing MunicipalityAges 18 years+ - NCT07635342RecruitingPhase 2
Pyrotinib plus trastuzumab and chemotherapy for HER2-positive early breast cancer
This trial tests a combination of three drugs—pyrotinib, trastuzumab, and chemotherapy—to treat HER2-positive breast cancer that has not been treated before. HER2 is a protein found on some cancer cells; blocking it may help stop the cancer from growing.
Shijiazhuang, HebeiAges 18–65 - NCT07518173RecruitingPhase 3
BL-M07D1 plus Pertuzumab for HER2-positive breast cancer
This trial tests whether a new cancer drug called BL-M07D1, combined with pertuzumab, works better or as well as standard chemotherapy for advanced HER2-positive breast cancer that has spread or come back. HER2-positive means the cancer cells have high levels of a protein called HER2, which makes them grow faster.
Guangzhou, GuangdongAges 18–75 - NCT07215364Recruiting
Exercise and quality of life in early breast cancer on hormone therapy
This trial tests if a supervised exercise program can improve quality of life for people with early-stage breast cancer who are currently taking hormone therapy (aromatase inhibitors with or without CDK4/6 inhibitors). It aims to see if exercise helps reduce side effects like fatigue and pain.
L'Hospitalet de Llobregat, BarcelonaAges 18 years+ - NCT04751435Recruiting
Genetic testing education for cancer patients of diverse backgrounds
This study tests new educational materials about genetic testing for cancer patients. It aims to find the best ways to explain genetic testing to people from different backgrounds, especially Black, Latino, and non-Latino non-Black communities.
Brooklyn, New YorkAges 18 years+ - NCT06167694RecruitingPhase 1/Phase 2
Study of HRS-8080 and Dalpiciclib for advanced breast cancer
This trial tests a new combination of two drugs (HRS-8080 and Dalpiciclib) for women with advanced breast cancer that cannot be removed by surgery. It may be an option if you have already tried hormone therapy or are starting advanced treatment for the first time.
Beijing, Beijing MunicipalityAges 18–75 - NCT07502352Recruiting
Online stress management for breast cancer survivors
This study tests a remotely-delivered program to help you manage stress after breast cancer treatment. It is for women who are 50 or older, have completed treatment for a specific type of breast cancer, and currently take hormone therapy.
Coral Gables, FloridaAges 50 years+ - NCT06559540RecruitingPhase 2
Compare short radiation courses for node-positive breast cancer
This study compares two shorter courses of radiation therapy for women with node-positive breast cancer. It aims to see if an ultra-short course is as safe and effective as the slightly longer short course.
St Louis, MissouriAges 18 years+ - NCT06793553RecruitingPhase 2
Induction chemo then immunotherapy for PD-L1 positive triple negative breast cancer
This trial tests a two-step approach: first a short course of chemotherapy (paclitaxel and bevacizumab), followed by a combination of immunotherapy (atezolizumab) and a different chemotherapy (nab-paclitaxel). It's for people with advanced triple-negative breast cancer that has spread or cannot be removed, and whose tumors have a specific marker called PD-L1. The goal is to see if this sequence works better than standard treatments.
Koto-ku, 3-8-31, TokyoAges 18 years+ - NCT07134153RecruitingPhase 1/Phase 2
T-DXd injected into spinal fluid for HER2 breast cancer with brain spread
This trial tests a new way of giving the targeted drug T-DXd—directly into the fluid around your spine (intrathecal) or through a device under your scalp called an Ommaya reservoir. It's designed for people with HER2-positive breast cancer that has spread to the brain or the lining of the brain/spinal cord.
Shanghai, Shanghai MunicipalityAges 18 years+ - NCT07258108RecruitingPhase 2
Sac-TMT and KL-A167 for HR+/HER2- Breast Cancer
This trial is testing a combination of two drugs, Sac-TMT and KL-A167, in people with a certain type of advanced breast cancer (HR+/HER2-) that is PD-L1 positive. It's for those whose cancer has gotten worse after treatment with a CDK4/6 inhibitor and hormone therapy.
Guangzhou, GuangdongAges 18–75 - NCT07647263RecruitingPhase 2
New Drug Treatment Before Surgery for HER2-Positive Breast Cancer
This trial tests a new drug called trastuzumab rezetecan given before surgery for early-stage HER2-positive breast cancer. It's designed for patients whose cancer doesn't respond well to standard HER2-targeted treatments.
Suzhou, JiangsuAges 18 years+
Hear when a new HER 2 Negative Breast Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for her 2 negative breast cancer?
- Yes. Clin2 currently lists 934 recruiting her 2 negative breast cancer studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a her 2 negative breast cancer trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a her 2 negative breast cancer trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
- Breast Cancer (Triple Negative Breast Cancer (TNBC))
- Breast Cancer Early Stage Breast Cancer (Stage 1-3)
- Hormone Receptor Positive HER-2 Negative Breast Cancer
- HR Positive/HER-2 Negative Breast Cancer
- Triple Negative Breast Cancer
- HER2-negative Breast Cancer
- Metastatic Triple-negative Breast Cancer
- Advanced Triple Negative Breast Cancer
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.